It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyperactive Notch signalling is frequently observed in breast cancer and correlates with poor prognosis. However, relatively few mutations in the core Notch signalling pathway have been identified in breast cancer, suggesting that as yet unknown mechanisms increase Notch activity. Here we show that increased expression levels of GIT1 correlate with high relapse-free survival in oestrogen receptor-negative (ER(-)) breast cancer patients and that GIT1 mediates negative regulation of Notch. GIT1 knockdown in ER(-) breast tumour cells increased signalling downstream of Notch and activity of aldehyde dehydrogenase, a predictor of poor clinical outcome. GIT1 interacts with the Notch intracellular domain (ICD) and influences signalling by inhibiting the cytoplasm-to-nucleus transport of the Notch ICD. In xenograft experiments, overexpression of GIT1 in ER(-) cells prevented or reduced Notch-driven tumour formation. These results identify GIT1 as a modulator of Notch signalling and a guardian against breast cancer growth.
Notch signalling is reported to be hyperactivated in oestrogen receptor-negative (ER-) breast cancer. Here the authors show that G protein-coupled receptor kinase-interacting protein 1 (GIT1) negatively regulates Notch signalling and tumour growth in ER- breast cancer by blocking Notch ICD nuclear translocation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
2 Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
3 Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
4 Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Universidad San Sebastián, Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Santiago, Chile (GRID:grid.442215.4) (ISNI:0000 0001 2227 4297)
5 Åbo Akademi University and University of Turku, Turku Bioscience, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415); Åbo Akademi University, Faculty of Science and Engineering, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415)
6 University of Turku, Department of Pathology, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371)
7 ShanghaiTech University, Shanghai Institute for Advanced Immunochemical Studies, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); RIKEN Center for Life Science Technologies (CLST), Chuo-ku, Japan (GRID:grid.440637.2); Toho University, Department of Biomolecular Science, Faculty of Science, Chiba, Japan (GRID:grid.265050.4) (ISNI:0000 0000 9290 9879)
8 Åbo Akademi University and University of Turku, Turku Bioscience, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415); Åbo Akademi University, Faculty of Science and Engineering, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415); Eindhoven University of Technology, Institute for Complex Molecular Systems, Eindhoven, the Netherlands (GRID:grid.6852.9) (ISNI:0000 0004 0398 8763)